Read more
3:36 PM · 27 January 2025

Massive sell-off in Allakos shares following disappointing clinical trial results for AK006 📉

Allakos
Stocks
ALLK.US, Allakos Inc
-
-

Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.

 

Source: xStation

31 October 2025, 7:08 PM

Daily summary: Sentiments on Wall Street stall at the end of the week🗽US Dollar gains

31 October 2025, 4:08 PM

AbbVie near 1-month low after earnings report 📉

31 October 2025, 3:14 PM

Wall Street optimism tempers amid falling odds of December Fed rate cut

31 October 2025, 11:25 AM

DE40: Decline of sentiment in Europe

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits